APA (7. basım) Alıntı

Nara, K., Yamamoto, T., Yamashita, H., Yagi, K., Takada, T., Seto, Y., & Suzuki, H. (2023). Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: A single center retrospective study. BMC.

Chicago Style (17. basım) Atıf

Nara, Katsuhiko, Takehito Yamamoto, Hiroharu Yamashita, Koichi Yagi, Tappei Takada, Yasuyuki Seto, ve Hiroshi Suzuki. Prior Treatment with Oxaliplatin-containing Regimens and Higher Total Bilirubin Levels Are Risk Factors for Neutropenia and Febrile Neutropenia in Patients with Gastric or Esophagogastric Junction Cancer Receiving Weekly Paclitaxel and Ramucirumab Therapy: A Single Center Retrospective Study. BMC, 2023.

MLA (9th ed.) Atıf

Nara, Katsuhiko, et al. Prior Treatment with Oxaliplatin-containing Regimens and Higher Total Bilirubin Levels Are Risk Factors for Neutropenia and Febrile Neutropenia in Patients with Gastric or Esophagogastric Junction Cancer Receiving Weekly Paclitaxel and Ramucirumab Therapy: A Single Center Retrospective Study. BMC, 2023.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..